Literature DB >> 18693178

Survival and an overview of decision-making in patients with cholangiocarcinoma.

Havard Mjorud Forsmo1, Arild Horn, Asgaut Viste, Dag Hoem, Kjell Ovrebo.   

Abstract

BACKGROUND: Cholangiocarcinoma is rare, accounting for approximately 3% of all gastrointestinal cancers. This study aimed to identify the survival rate among surgically treated and palliated patients, and secondly to identify parameters that could predict a curative resection.
METHODS: A total of 121 patients, 55 men and 66 women, median age 70 years (range 31-91), who had been treated for cholangiocarcinoma in the period of 1990-2005 were evaluated retrospectively.
RESULTS: Curative resection was performed in 40 patients (33%), whereas 81 received palliative treatment (67%). 16% (19 of 121) of the patients had an explorative laparotomy without tumour resection. Age above 65 years (OR 3.4; 95% CI 1.4-8.4; P=0.008), weight loss (OR 8.5; 95% CI 1.5-46; P=0.01) or tumour location (The resection rate of hilar cholangiocarcinoma was lower than that of intrapancreatic cancer.) (OR 2.7; 95% CI 1.7-4.5; P=0.001) predicted palliative treatment. The adjusted 5-year survival rate of patients who received tumour resection and palliative treatment was 30% and 1.2 %, respectively (P<0.001). The survival rate of patients who were subjected to hepatectomy (70%) was better than that of patients who had a local or distal resection (20%) (P=0.02).
CONCLUSIONS: In few patients with a resectable cholangiocarcinoma, an explorative laparotomy is often necessary to evaluate resectability. However, long-term survival is significantly better in patients who received radical surgical resection.

Entities:  

Mesh:

Year:  2008        PMID: 18693178

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  11 in total

Review 1.  [Klatskin tumors: rational diagnostics and staging].

Authors:  U W Denzer; T Rösch
Journal:  Chirurg       Date:  2012-03       Impact factor: 0.955

2.  Addition of hepatectomy decreases liver recurrence and leads to long survival in hilar cholangiocarcinoma.

Authors:  Zheng Shi; Ming-Zhi Yang; Qing-Liang He; Rong-Wen Ou; You-Ting Chen
Journal:  World J Gastroenterol       Date:  2009-04-21       Impact factor: 5.742

Review 3.  Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.

Authors:  Murad Aljiffry; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

4.  Comorbidity negatively influences prognosis in patients with extrahepatic cholangiocarcinoma.

Authors:  Mario Fernández-Ruiz; Juan-Manuel Guerra-Vales; Francisco Colina-Ruizdelgado
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

5.  Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: a meta-analysis.

Authors:  Shang-Long Liu; Zi-Fang Song; Qing-Gang Hu; Duo Shan; Shao-Bo Hu; Jun Li; Qi-Chang Zheng
Journal:  Front Med China       Date:  2010-11-16

Review 6.  Cholangiocarcinoma: new insights into disease pathogenesis and biology.

Authors:  Chiara Braconi; Tushar Patel
Journal:  Infect Dis Clin North Am       Date:  2010-12       Impact factor: 5.982

7.  Multimodal oncological therapy comprising stents, brachytherapy, and regional chemotherapy for cholangiocarcinoma.

Authors:  Tomáš Andrašina; Vlastimil Válek; Jiří Pánek; Zdeněk Kala; Igor Kiss; Stěpán Tuček; Pavel Slampa
Journal:  Gut Liver       Date:  2010-09-10       Impact factor: 4.519

8.  Surgical resection for hilar cholangiocarcinoma: experience improves resectability.

Authors:  Robert M Cannon; Guy Brock; Joseph F Buell
Journal:  HPB (Oxford)       Date:  2011-12-12       Impact factor: 3.647

9.  Stereotactic body radiation therapy in cholangiocarcinoma: a systematic review.

Authors:  Rezarta Frakulli; Milly Buwenge; Gabriella Macchia; Silvia Cammelli; Francesco Deodato; Savino Cilla; Francesco Cellini; Gian C Mattiucci; Silvia Bisello; Giovanni Brandi; Salvatore Parisi; Alessio G Morganti
Journal:  Br J Radiol       Date:  2019-02-07       Impact factor: 3.039

10.  Prognostic factors following surgical resection of distal bile duct cancer.

Authors:  Young Jae Chung; Dong Wook Choi; Seong Ho Choi; Jin Seok Heo; Dong Hun Kim
Journal:  J Korean Surg Soc       Date:  2013-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.